A Multicenter, Randomized, Cross-over, Open-label Study to Evaluate IGSC 20% Flexible Dosing Including Daily Push Dosing In Treatment-Experienced Subjects With Primary Immunodeficiency (PI) and Evaluation of Loading/Maintenance IGSC 20% in Treatment-Naïve Subjects With PI
Latest Information Update: 13 Apr 2020
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- Sponsors Grifols
Most Recent Events
- 08 Apr 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 05 Jul 2019 Planned initiation date changed from 1 May 2019 to 1 Dec 2019.
- 06 Mar 2019 Planned initiation date changed from 1 Feb 2019 to 1 May 2019.